Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-meningococcal-vaccines-global-drug-forecast-and-market-analysis-to-2022-event-driven-update-market-report.html .
Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. Researcher expects growth in the meningococcal vaccines market to be driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape, and an increase in the coverage rates of existing routine vaccination programs. Cost-effectiveness concerns, especially for serogroup B vaccines, will serve as a key barrier to market growth. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
